Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant? Review

   

Authors:	Ball, B.; Stein, E. M.
Review Title:	Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Abstract:	Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies that specifically target minimal residual disease are limited. Consensus guidelines on minimal residual disease detection by immunophenotypic and molecular methods are an essential initial step for clinical trials evaluating minimal residual disease. Here, we review promising targets of minimal residual disease prior to allogeneic stem cell transplantation. Specifically, the focus of this review is on the rationale and clinical development of therapies targeting: oncogenic driver mutations, apoptosis, methylation, and leukemic immune targets. We review the progress made in the clinical development of therapies against each target and the challenges that lie ahead. © 2019 Ferrata Storti Foundation.
Journal Title:	Haematologica
Volume:	104
Issue:	8
ISSN:	0390-6078
Publisher:	Ferrata Storti Foundation
Date Published:	2019-07-31
Start Page:	1521
End Page:	1531
Language:	English
DOI:	10.3324/haematol.2018.208587
PUBMED:	31366466
PROVIDER:	scopus
PMCID:	PMC6669154
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070601608&doi=10.3324%2fhaematol.2018.208587&partnerID=40&md5=e5aadb8e76858639b74e6774d72b90dc
Notes:	Review -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/151319